Katherine McMahan
Overview
Explore the profile of Katherine McMahan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
5141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lasrado N, Rowe M, McMahan K, Hachmann N, Miller J, Jacob-Dolan C, et al.
Sci Transl Med
. 2024 Oct;
16(770):eadp8920.
PMID: 39441905
Current COVID-19 vaccines provide robust protection against severe disease but minimal protection against acquisition of infection. Intramuscularly administered COVID-19 vaccines induce robust serum neutralizing antibodies (NAbs), but their ability to...
2.
Collier A, McMahan K, Jacob-Dolan C, Liu J, Borducchi E, Moss B, et al.
JAMA
. 2024 Oct;
332(19):1669-1672.
PMID: 39361499
No abstract available.
3.
Collier A, McMahan K, Jacob-Dolan C, Liu J, Borducchi E, Moss B, et al.
medRxiv
. 2024 Sep;
PMID: 39314978
The replication-incompetent modified vaccinia Ankara-Bavarian Nordic vaccine (MVA-BN; Jynneos) was deployed during the 2022 clade IIb mpox outbreak. On August 14, 2024, the World Health Organization declared the mpox clade...
4.
Jacob-Dolan C, Ty D, Hope D, McMahan K, Liu J, Powers O, et al.
Sci Transl Med
. 2024 Mar;
16(740):eadl4317.
PMID: 38536937
The 2022-2023 mpox outbreak triggered vaccination efforts using smallpox vaccines that were approved for mpox, including modified vaccinia Ankara (MVA; JYNNEOS), which is a safer alternative to live replicating vaccinia...
5.
McMahan K, Wegmann F, Aid M, Sciacca M, Liu J, Hachmann N, et al.
Nature
. 2023 Dec;
626(7998):385-391.
PMID: 38096903
A limitation of current SARS-CoV-2 vaccines is that they provide minimal protection against infection with current Omicron subvariants, although they still provide protection against severe disease. Enhanced mucosal immunity may...
6.
Aid M, Sciacca M, McMahan K, Hope D, Liu J, Jacob-Dolan C, et al.
Cell
. 2023 Sep;
186(21):4652-4661.e13.
PMID: 37734373
The mpox outbreak of 2022-2023 involved rapid global spread in men who have sex with men. We infected 18 rhesus macaques with mpox by the intravenous, intradermal, and intrarectal routes...
7.
Solforosi L, Costes L, Tolboom J, McMahan K, Anioke T, Hope D, et al.
Nat Commun
. 2023 Apr;
14(1):1944.
PMID: 37029141
Omicron spike (S) encoding vaccines as boosters, are a potential strategy to improve COVID-19 vaccine efficacy against Omicron. Here, macaques (mostly females) previously immunized with Ad26.COV2.S, are boosted with Ad26.COV2.S,...
8.
Yu J, Thomas P, Sciacca M, Wu C, Liu J, He X, et al.
Cell Rep Med
. 2023 Apr;
4(4):101018.
PMID: 37023746
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines demonstrate reduced protection against acquisition of BA.5 subvariant but are still effective against severe disease. However, immune correlates of protection against BA.5...
9.
Jacob-Dolan C, Yu J, McMahan K, Giffin V, Chandrashekar A, Martinot A, et al.
NPJ Vaccines
. 2023 Feb;
8(1):23.
PMID: 36823160
Despite the availability of several effective SARS-CoV-2 vaccines, additional vaccines will be required for optimal global vaccination. In this study, we investigate the immunogenicity and protective efficacy of the GBP510...
10.
Collier A, Miller J, Hachmann N, McMahan K, Liu J, A Bondzie E, et al.
N Engl J Med
. 2023 Jan;
388(6):565-567.
PMID: 36630611
No abstract available.